The post-operative cataract surgery inflammation treatment market size has grown strongly in recent years. It will grow from $4.78 billion in 2025 to $5.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising cataract surgery volumes, increased availability of ophthalmic anti-inflammatory drugs, expansion of outpatient surgical centers, improved surgical techniques, growing aging population.
The post-operative cataract surgery inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for advanced ophthalmic formulations, rising focus on reducing post-operative complications, expansion of minimally invasive eye surgeries, growing investments in ophthalmology research, increasing adoption of patient-specific treatment regimens. Major trends in the forecast period include increasing use of combination anti-inflammatory therapies, rising adoption of ophthalmic nsaids, growing focus on faster post-surgical recovery, expansion of hospital-based ophthalmic care protocols, enhanced emphasis on preventing post-surgical complications.
The increasing incidence of traumatic injuries is expected to drive the growth of the post-operative cataract surgery inflammation treatment market in the coming years. Traumatic injuries are sudden physical harms caused by external forces such as accidents, falls, violence, or sports-related impacts, and they can range from minor wounds to severe fractures, burns, brain injuries, and spinal damage. The rise in traumatic injuries can be linked to factors including higher rates of road traffic accidents, workplace risks, sports activities, violence, natural disasters, and aging populations that are more susceptible to falls. Post-operative cataract surgery inflammation treatments support patients with traumatic injuries by reducing ocular inflammation, relieving pain, and preventing complications that may negatively affect visual recovery. For instance, in October 2024, according to Insideworldfootball, a UK-based online news service, sports-related injuries totaled 4,123 during the 2023-24 season, representing a 4% increase compared to the 2022-23 season. Therefore, the growing number of traumatic injuries is contributing to the expansion of the post-operative cataract surgery inflammation treatment market.
Major companies operating in the post-operative cataract surgery inflammation treatment market are concentrating on the development of innovative therapies, including postoperative ocular analgesics, to improve the management of pain and inflammation following eye surgery. Postoperative ocular analgesics are therapeutic agents specifically formulated to reduce eye pain and inflammation after surgical procedures, thereby enhancing patient comfort and supporting optimal recovery. For instance, in March 2024, Formosa Pharmaceuticals, a Taiwan-based pharmaceutical company, in collaboration with AimMax Therapeutics, a US-based biotechnology company, received approval from the US Food and Drug Administration for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of post-operative pain and inflammation following ocular surgery. APP13007 is the first FDA-approved ophthalmic clobetasol propionate product and represents the introduction of the first new ophthalmic steroid in more than 15 years, providing a novel option for managing post-operative ocular inflammation and improving patient recovery.
In September 2024, Armistice Capital LLC, a US-based home health care service company, acquired shares in Eyenovia Inc. for an undisclosed amount. Through this acquisition, Armistice Capital LLC seeks to strengthen its position in the ophthalmic sector by increasing its influence over Eyenovia’s strategic direction and capitalizing on potential future growth opportunities. Eyenovia Inc. is a US-based pharmaceutical company that develops treatments for post-operative inflammation and pain following ocular surgery using clobetasol.
Major companies operating in the post-operative cataract surgery inflammation treatment market are Alcon Inc, Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Merck & Co. Inc., Sun Pharmaceutical Industries Limited, EyePoint Pharmaceuticals Inc, Ocular Therapeutix Inc., Oculis Holding AG, Senju Pharmaceutical Co. Ltd., Nicox S.A., Formosa Pharmaceuticals Inc, Eyenovia Inc., Surface Ophthalmics Inc., ImprimisRx LLC, NTC Srl, VivaVision Biotech Inc., Bio-Tissue Inc., Mallinckrodt plc.
North America was the largest region in the post-operative cataract surgery inflammation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative cataract surgery inflammation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-operative cataract surgery inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the post-operative cataract surgery inflammation treatment market by increasing costs of imported pharmaceutical ingredients, sterile packaging materials, ophthalmic delivery systems, and formulation equipment. Hospitals and specialty eye clinics in North America and Europe are most affected due to dependence on imported ophthalmic drugs, while Asia-Pacific faces cost pressures on generic production. These tariffs are increasing treatment costs and procurement complexity. However, they are also encouraging local drug manufacturing, regional formulation capabilities, and improved supply chain resilience.
The post-operative cataract surgery inflammation treatment market research report is one of a series of new reports that provides post-operative cataract surgery inflammation treatment market statistics, including post-operative cataract surgery inflammation treatment industry global market size, regional shares, competitors with a post-operative cataract surgery inflammation treatment market share, detailed post-operative cataract surgery inflammation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative cataract surgery inflammation treatment industry. This post-operative cataract surgery inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-operative cataract surgery inflammation treatment involves medical therapies designed to manage inflammation and discomfort following cataract surgery. These treatments are intended to reduce inflammation, prevent complications such as rebound iritis and pseudophakic cystoid macular edema (PCME), and support quicker patient recovery.
The primary drug classes used for post-operative cataract surgery inflammation treatment include bromfenac, indomethacin, diclofenac, flurbiprofen, and nepafenac. Bromfenac is a strong nonsteroidal anti-inflammatory drug commonly used in ophthalmology to alleviate post-operative inflammation and pain by inhibiting the COX-1 and COX-2 enzymes. These medications are delivered through different routes, including oral and injectable forms, and are supplied through various distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies.
The post-operative cataract surgery inflammation treatment market consists of sales of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-inflammatory medications. Values in this market are 'factory gate' values, meaning the value of goods sold by manufacturers, whether to other entities (including wholesalers, distributors, or directly to end customers) or downstream manufacturers. The value of goods includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The post-operative cataract surgery inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for advanced ophthalmic formulations, rising focus on reducing post-operative complications, expansion of minimally invasive eye surgeries, growing investments in ophthalmology research, increasing adoption of patient-specific treatment regimens. Major trends in the forecast period include increasing use of combination anti-inflammatory therapies, rising adoption of ophthalmic nsaids, growing focus on faster post-surgical recovery, expansion of hospital-based ophthalmic care protocols, enhanced emphasis on preventing post-surgical complications.
The increasing incidence of traumatic injuries is expected to drive the growth of the post-operative cataract surgery inflammation treatment market in the coming years. Traumatic injuries are sudden physical harms caused by external forces such as accidents, falls, violence, or sports-related impacts, and they can range from minor wounds to severe fractures, burns, brain injuries, and spinal damage. The rise in traumatic injuries can be linked to factors including higher rates of road traffic accidents, workplace risks, sports activities, violence, natural disasters, and aging populations that are more susceptible to falls. Post-operative cataract surgery inflammation treatments support patients with traumatic injuries by reducing ocular inflammation, relieving pain, and preventing complications that may negatively affect visual recovery. For instance, in October 2024, according to Insideworldfootball, a UK-based online news service, sports-related injuries totaled 4,123 during the 2023-24 season, representing a 4% increase compared to the 2022-23 season. Therefore, the growing number of traumatic injuries is contributing to the expansion of the post-operative cataract surgery inflammation treatment market.
Major companies operating in the post-operative cataract surgery inflammation treatment market are concentrating on the development of innovative therapies, including postoperative ocular analgesics, to improve the management of pain and inflammation following eye surgery. Postoperative ocular analgesics are therapeutic agents specifically formulated to reduce eye pain and inflammation after surgical procedures, thereby enhancing patient comfort and supporting optimal recovery. For instance, in March 2024, Formosa Pharmaceuticals, a Taiwan-based pharmaceutical company, in collaboration with AimMax Therapeutics, a US-based biotechnology company, received approval from the US Food and Drug Administration for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of post-operative pain and inflammation following ocular surgery. APP13007 is the first FDA-approved ophthalmic clobetasol propionate product and represents the introduction of the first new ophthalmic steroid in more than 15 years, providing a novel option for managing post-operative ocular inflammation and improving patient recovery.
In September 2024, Armistice Capital LLC, a US-based home health care service company, acquired shares in Eyenovia Inc. for an undisclosed amount. Through this acquisition, Armistice Capital LLC seeks to strengthen its position in the ophthalmic sector by increasing its influence over Eyenovia’s strategic direction and capitalizing on potential future growth opportunities. Eyenovia Inc. is a US-based pharmaceutical company that develops treatments for post-operative inflammation and pain following ocular surgery using clobetasol.
Major companies operating in the post-operative cataract surgery inflammation treatment market are Alcon Inc, Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Merck & Co. Inc., Sun Pharmaceutical Industries Limited, EyePoint Pharmaceuticals Inc, Ocular Therapeutix Inc., Oculis Holding AG, Senju Pharmaceutical Co. Ltd., Nicox S.A., Formosa Pharmaceuticals Inc, Eyenovia Inc., Surface Ophthalmics Inc., ImprimisRx LLC, NTC Srl, VivaVision Biotech Inc., Bio-Tissue Inc., Mallinckrodt plc.
North America was the largest region in the post-operative cataract surgery inflammation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative cataract surgery inflammation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-operative cataract surgery inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the post-operative cataract surgery inflammation treatment market by increasing costs of imported pharmaceutical ingredients, sterile packaging materials, ophthalmic delivery systems, and formulation equipment. Hospitals and specialty eye clinics in North America and Europe are most affected due to dependence on imported ophthalmic drugs, while Asia-Pacific faces cost pressures on generic production. These tariffs are increasing treatment costs and procurement complexity. However, they are also encouraging local drug manufacturing, regional formulation capabilities, and improved supply chain resilience.
The post-operative cataract surgery inflammation treatment market research report is one of a series of new reports that provides post-operative cataract surgery inflammation treatment market statistics, including post-operative cataract surgery inflammation treatment industry global market size, regional shares, competitors with a post-operative cataract surgery inflammation treatment market share, detailed post-operative cataract surgery inflammation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative cataract surgery inflammation treatment industry. This post-operative cataract surgery inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-operative cataract surgery inflammation treatment involves medical therapies designed to manage inflammation and discomfort following cataract surgery. These treatments are intended to reduce inflammation, prevent complications such as rebound iritis and pseudophakic cystoid macular edema (PCME), and support quicker patient recovery.
The primary drug classes used for post-operative cataract surgery inflammation treatment include bromfenac, indomethacin, diclofenac, flurbiprofen, and nepafenac. Bromfenac is a strong nonsteroidal anti-inflammatory drug commonly used in ophthalmology to alleviate post-operative inflammation and pain by inhibiting the COX-1 and COX-2 enzymes. These medications are delivered through different routes, including oral and injectable forms, and are supplied through various distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies.
The post-operative cataract surgery inflammation treatment market consists of sales of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-inflammatory medications. Values in this market are 'factory gate' values, meaning the value of goods sold by manufacturers, whether to other entities (including wholesalers, distributors, or directly to end customers) or downstream manufacturers. The value of goods includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Post-Operative Cataract Surgery Inflammation Treatment Market Characteristics
3. Post-Operative Cataract Surgery Inflammation Treatment Market Supply Chain Analysis
4. Global Post-Operative Cataract Surgery Inflammation Treatment Market Trends and Strategies
5. Post-Operative Cataract Surgery Inflammation Treatment Market Analysis of End Use Industries
7. Global Post-Operative Cataract Surgery Inflammation Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Post-Operative Cataract Surgery Inflammation Treatment Total Addressable Market (TAM) Analysis for the Market
9. Post-Operative Cataract Surgery Inflammation Treatment Market Segmentation
10. Post-Operative Cataract Surgery Inflammation Treatment Market Regional and Country Analysis
11. Asia-Pacific Post-Operative Cataract Surgery Inflammation Treatment Market
12. China Post-Operative Cataract Surgery Inflammation Treatment Market
13. India Post-Operative Cataract Surgery Inflammation Treatment Market
14. Japan Post-Operative Cataract Surgery Inflammation Treatment Market
15. Australia Post-Operative Cataract Surgery Inflammation Treatment Market
16. Indonesia Post-Operative Cataract Surgery Inflammation Treatment Market
17. South Korea Post-Operative Cataract Surgery Inflammation Treatment Market
18. Taiwan Post-Operative Cataract Surgery Inflammation Treatment Market
19. South East Asia Post-Operative Cataract Surgery Inflammation Treatment Market
20. Western Europe Post-Operative Cataract Surgery Inflammation Treatment Market
21. UK Post-Operative Cataract Surgery Inflammation Treatment Market
22. Germany Post-Operative Cataract Surgery Inflammation Treatment Market
23. France Post-Operative Cataract Surgery Inflammation Treatment Market
24. Italy Post-Operative Cataract Surgery Inflammation Treatment Market
25. Spain Post-Operative Cataract Surgery Inflammation Treatment Market
26. Eastern Europe Post-Operative Cataract Surgery Inflammation Treatment Market
27. Russia Post-Operative Cataract Surgery Inflammation Treatment Market
28. North America Post-Operative Cataract Surgery Inflammation Treatment Market
29. USA Post-Operative Cataract Surgery Inflammation Treatment Market
30. Canada Post-Operative Cataract Surgery Inflammation Treatment Market
31. South America Post-Operative Cataract Surgery Inflammation Treatment Market
32. Brazil Post-Operative Cataract Surgery Inflammation Treatment Market
33. Middle East Post-Operative Cataract Surgery Inflammation Treatment Market
34. Africa Post-Operative Cataract Surgery Inflammation Treatment Market
36. Post-Operative Cataract Surgery Inflammation Treatment Market Competitive Landscape and Company Profiles
37. Post-Operative Cataract Surgery Inflammation Treatment Market Other Major and Innovative Companies
40. Post-Operative Cataract Surgery Inflammation Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Post-Operative Cataract Surgery Inflammation Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses post-operative cataract surgery inflammation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for post-operative cataract surgery inflammation treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The post-operative cataract surgery inflammation treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Bromfenac; Indomethacin; Diclofenac; Flurbiprofen; Nepafenac2) By Route of Administration: Topical Ophthalmic; Intracameral And Ophthalmic Use
3) By Distribution Channel: Hospital pharmacy; Online Pharmacy; Retail pharmacy
Subsegments:
1) By Bromfenac: Bromfenac Ophthalmic Solution 0.07%; Bromfenac Ophthalmic Solution 0.09%; Combination Therapies With Bromfenac2) By Indomethacin: Indomethacin Ophthalmic Solution 0.1%; Indomethacin Ophthalmic NSAID Formulations; Ophthalmic Anti-Inflammatory Solutions
3) By Diclofenac: Diclofenac Ophthalmic Solution 0.1%; Diclofenac Ophthalmic Drops; Ophthalmic NSAID Preparations
4) By Flurbiprofen: Flurbiprofen Ophthalmic Solution 0.03%; Adjunctive Use In Ocular Surgery; Combination Therapies With Flurbiprofen
5) By Nepafenac: Nepafenac Ophthalmic Suspension 0.1%; Nepafenac Ophthalmic Suspension 0.3%
Companies Mentioned: Alcon Inc; Bausch & Lomb Incorporated; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer Inc.; Merck & Co. Inc.; Sun Pharmaceutical Industries Limited; EyePoint Pharmaceuticals Inc; Ocular Therapeutix Inc.; Oculis Holding AG; Senju Pharmaceutical Co. Ltd.; Nicox S.A.; Formosa Pharmaceuticals Inc; Eyenovia Inc.; Surface Ophthalmics Inc.; ImprimisRx LLC; NTC Srl; VivaVision Biotech Inc.; Bio-Tissue Inc.; Mallinckrodt plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Post-Operative Cataract Surgery Inflammation Treatment market report include:- Alcon Inc
- Bausch & Lomb Incorporated
- Santen Pharmaceutical Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Sun Pharmaceutical Industries Limited
- EyePoint Pharmaceuticals Inc
- Ocular Therapeutix Inc.
- Oculis Holding AG
- Senju Pharmaceutical Co. Ltd.
- Nicox S.A.
- Formosa Pharmaceuticals Inc
- Eyenovia Inc.
- Surface Ophthalmics Inc.
- ImprimisRx LLC
- NTC Srl
- VivaVision Biotech Inc.
- Bio-Tissue Inc.
- Mallinckrodt plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.14 Billion |
| Forecasted Market Value ( USD | $ 6.78 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
